Loading...
Loading...
Browse all stories on DeepNewz
VisitAlpha Cognition Secures $44 Million Licensing Deal for Alzheimer's Drug Zunveyl in China, Including $6 Million Upfront
Jan 8, 2025, 01:48 PM
Alpha Cognition Inc. has announced a $44 million exclusive licensing agreement for the development and commercialization of Zunveyl, an FDA-approved treatment for mild-to-moderate Alzheimer’s disease, in China. The deal includes a $6 million upfront payment and covers regions including Asia (excluding Japan), Australia, and New Zealand. Zunveyl, also known as benzgalantamine, is anticipated to address neuroinflammation associated with Alzheimer’s disease. This agreement was made with China Medical System, as Alpha Cognition aims to expand its market presence in the Asia-Pacific region.
View original story
Markets
No • 50%
Yes • 50%
Press releases or announcements from Alpha Cognition
Yes • 50%
No • 50%
Financial statements or press releases from Alpha Cognition
No • 50%
Yes • 50%
Announcements from Chinese regulatory authorities or Alpha Cognition
$20 million to $30 million • 25%
More than $30 million • 25%
Less than $10 million • 25%
$10 million to $20 million • 25%
Financial reports from Alpha Cognition or China Medical System
20% to 30% • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
Market analysis reports or industry publications
Other Asia-Pacific country • 25%
China • 25%
Australia • 25%
New Zealand • 25%
Press releases or announcements from Alpha Cognition or local regulatory bodies